Every 8-K that IB Acquisition Corp. (IBAC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IBAC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IBAC filings page.
IB Acquisition Corp. scheduled its 2026 annual meeting for December 16, 2026, at 10:00 a.m. Eastern Time, to be held virtually by live webcast. The record date for stockholders entitled to notice of and to vote at the meeting is the close of business on October 28, 2026.
Stockholder proposals for inclusion in the proxy statement must be received by close of business October 26, 2026. Nasdaq notified the company on October 5, 2026, that it was not in compliance with Listing Rule 5620(a) because it had not held an annual meeting within 12 months of its fiscal year-end. IB Acquisition believes the December meeting will enable it to regain compliance; it will be the company’s first annual meeting since its initial public offering.
IB Acquisition Corp. received a Nasdaq determination letter on October 5, 2026, stating that it is not compliant with the Annual Meeting Requirement because it did not hold an annual meeting of shareholders within 12 months of the end of its fiscal year. The company has 45 calendar days to submit a plan to regain compliance; if Nasdaq accepts the plan, Nasdaq may grant an exception of up to 180 calendar days from fiscal year-end, or until March 29, 2027, to regain compliance. The company intends to submit a plan that includes a proxy statement preparation and proxy solicitation timeline leading to an annual meeting. The notice has no immediate effect on listing or trading, and the common stock will continue trading as IBAC during the compliance period.
IB Acquisition Corp. stockholders approved an amendment extending the deadline for an initial business combination to March 28, 2027, or a later date approved by stockholders under the amended articles. It also sets redemption and liquidation procedures if no combination is completed by then.
Before the earliest of a business combination, specified 100% redemptions, or redemptions tied to certain amendment votes, trust funds will not be released except for interest used to pay franchise and income taxes. Public stockholders may redeem shares in connection with amendments changing the substance or timing of the obligation to redeem 100% of public shares, or other material pre-combination provisions, subject to the applicable limitation. At the September 24, 2026 meeting, 3,444,462 shares were represented, about 69% of shares outstanding on August 27, 2026; votes were 3,437,439 for, 4,523 against, and 2,500 abstentions. Holders redeemed 117,386 shares at approximately $10.97 each; approximately $1,288,199.54 will be paid, leaving approximately $7,042,627.97 in trust, subject to tax withdrawals.
IB Acquisition Corp. amended its pending business-combination arrangements with GNQ Insilico and disclosed a convertible-note financing and equity purchase facility. Under the Equity Purchase Facility Agreement, IBAC may, but is not obligated to, sell up to $50.0 million in aggregate gross purchase price of newly issued Class A common shares; the commitment period begins after the resale registration statement is declared effective and continues for up to 36 months. At the PIPE’s initial closing, the Buyer will purchase notes with an aggregate original principal amount of $16,470,588, with potential additional closings up to an aggregate principal amount of $90,000,000; the initial closing is conditioned on satisfaction or waiver of all business-combination conditions, including redomestication.
The PIPE Notes convert at an initial $10.00 per-share price, bear 12% annual interest (18% during a continuing event of default), and are secured by a first-priority interest in substantially all personal property. IBAC will issue a $675,000 convertible Commitment Note at business-combination closing for the facility. The amendment removes the Minimum Cash closing condition, requires outstanding Bridge Financing obligations to be exchanged for senior secured convertible notes at closing, and provides for issuance of 350,000 shares to the Buyer.
IB Acquisition Corp. (IBAC) announced multiple financing arrangements and amendments related to its pending business combination with GNQ Insilico Inc. The company entered into an Equity Purchase Facility giving it the right to sell up to $50.0 million of Class A common stock to an institutional investor over a commitment period of up to 36 months, subject to a 4.99%–9.99% beneficial ownership cap and a 19.99% exchange cap unless stockholders approve more. As consideration, IB Acquisition will issue a $675,000 convertible commitment note.
The company, GNQ and a buyer also signed a Securities Purchase Agreement for senior secured convertible notes, with an initial closing of $16,470,588 in principal and potential additional closings up to $90,000,000. These PIPE Notes bear 12% interest (increasing to 18% upon default), mature in 12 months, are convertible at an initial price of $10.00 per share, and are secured by a first-priority lien on substantially all personal property of IB Acquisition and its subsidiaries. An amendment to the Business Combination Agreement removes the minimum cash closing condition, requires outstanding bridge financing to roll into notes under this structure, and provides for the issuance of 350,000 Class A shares to the buyer, while releasing 610,500 sponsor private placement units from a six‑month lock‑up.
IB Acquisition Corp. obtained stockholder approval to extend the deadline to complete its initial business combination from March 28, 2026 to September 28, 2026 through amendments to its trust agreement and articles of incorporation. If no deal is completed by September 28, 2026, the trust account will be liquidated under specified redemption and liquidation procedures, with no trust amounts used to pay dissolution expenses. The changes also clarify that trust funds generally remain locked except for interest used to pay franchise and income taxes, and reinforce public stockholders’ rights to redeem their shares in connection with key charter amendments affecting redemptions or the business combination timeline.
IB Acquisition Corp. reported the results of a special stockholder meeting and related redemptions of its common stock. Stockholders owning 5,077,821 shares, or about 88.46% of shares outstanding as of the February 11, 2026 record date, were present or represented by proxy.
Each proposal voted on at the meeting received 5,007,821 votes for and 70,000 against, with no abstentions or broker non-votes, so all proposals were approved. Separately, holders of 731,741 shares chose to redeem their shares for cash at approximately $10.78 per share from the company’s trust account.
These redemptions will remove about $7.9 million from the trust account, leaving approximately $8.2 million remaining. The remaining trust balance may change to reflect tax withdrawals.
IB Acquisition Corp. reports that its prospective merger partner, GNQ Insilico Inc., has entered a Joint Initiative Agreement and Joint Marketing Attachment with a Fortune 100 global technology company. The two-year, non-exclusive collaboration will jointly market AI-driven drug discovery and precision medicine solutions worldwide, combining GNQ’s proprietary AI platforms with the partner’s consulting, cloud, and quantum computing capabilities.
The report also reiterates a proposed business combination between IB Acquisition and GNQ. IB Acquisition plans to file a Form S-4 registration statement with the SEC, including a joint proxy statement/prospectus that will be sent to its stockholders in connection with the transaction.
IB Acquisition Corp. has entered a definitive business combination agreement to acquire GNQ Insilico Inc., valuing GNQ at US$500,000,000 plus potential revenue and share price earnouts. GNQ will become a Nasdaq-listed AI- and quantum-driven drug development company following a plan of arrangement under Canadian law.
The transaction is expected to provide approximately US$15 million of proceeds to GNQ through cash in IB Acquisition’s trust account and a PIPE of up to US$10 million, alongside a separate bridge financing of up to US$2,000,000 in 10% secured convertible notes and warrants. Closing, targeted for the third quarter of 2026, is subject to shareholder approvals, court orders, regulatory clearances, a minimum of US$5,000,001 in IB Acquisition net tangible assets, and at least US$15.0 million of available cash.
IB Acquisition Corp. obtained stockholder approval to extend the deadline to complete its initial business combination from September 28, 2025 to March 28, 2026, with the possibility of a later date if further approved by stockholders. The company amended its trust agreement so the trust account will be liquidated if no deal is completed by that date and no amounts will be deducted from the trust to pay dissolution expenses. A related charter amendment confirms that trust funds will stay locked except for interest used to pay franchise and income taxes and clarifies stockholder redemption and liquidation procedures.
At the special meeting, 14,325,971 shares, representing approximately 90.96% of the outstanding common stock as of September 3, 2025, were represented, and all proposals passed. Holders of 10,009,120 shares elected to redeem at approximately $10.60 per share, causing about $106.1 million to be paid out of the trust account and leaving about $15.8 million remaining there, subject to tax withdrawals.